Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 4411 AL 4425

Strategic Approaches to Target the Enzymes using Natural Compounds for the Management of Alzheimer's Disease: A Review

Ahmad SS, Younis K, Philippe J, Aschner M, Khan H.

CNS Neurol Disord Drug Targets. 2022;21(7):610-620. doi: 10.2174/1871527320666210811160007.

Molecular pathology and synaptic loss in primary tauopathies: an 18F-AV-1451 and 11C-UCB-J PET study

Holland N, Malpetti M, Rittman T, Mak EE, Passamonti L, Kaalund SS, Hezemans FH, Jones PS, Savulich G, Hong YT, Fryer TD, Aigbirhio FI, O'Brien JT, Rowe JB.

Brain. 2022 Mar 29;145(1):340-348. doi: 10.1093/brain/awab282.

Protein misfolding, ER stress and chaperones: an approach to develop chaperone-based therapeutics for Alzheimer's disease

Singh R, Kaur N, Dhingra N, Kaur T.

Int J Neurosci. 2023 Jul;133(7):714-734. doi: 10.1080/00207454.2021.1968859. Epub 2022 May 21.

The Outcomes of Small-Molecule Kinase Inhibitors and the Role of ROCK2 as a Molecular Target for the Treatment of Alzheimer's Disease

Tolomeu HV, Fraga CAM.

CNS Neurol Disord Drug Targets. 2022;21(2):188-205. doi: 10.2174/1871527320666210820092220.

PLGA-Based Curcumin Delivery System: An Interesting Therapeutic Approach in the Treatment of Alzheimer's Disease

Shahbaz SK, Koushki K, Sathyapalan T, Majeed M, Sahebkar A.

Curr Neuropharmacol. 2022;20(2):309-323. doi: 10.2174/1570159X19666210823103020.

Interleukin-17A in Alzheimer's Disease: Recent Advances and Controversies

Yan XZ, Lai L, Ao Q, Tian XH, Zhang YH.

Curr Neuropharmacol. 2022;20(2):372-383. doi: 10.2174/1570159X19666210823110004.

Immunotherapeutics for AD: A Work in Progress

Sharma A, Anand JS, Kumar Y.

CNS Neurol Disord Drug Targets. 2022;21(9):752-765. doi: 10.2174/1871527320666210903101522.

Targeted Delivery of Montelukast for the Treatment of Alzheimer's Disease

Datusalia AK, Singh G, Yadav N, Gaun S, Manik M, Singh RK.

CNS Neurol Disord Drug Targets. 2022;21(10):913-925. doi: 10.2174/1871527320666210902163756.

Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration

Durairajan SSK, Selvarasu K, Bera MR, Rajaram K, Iyaswamy A, Li M.

Curr Mol Pharmacol. 2022;15(2):361-379. doi: 10.2174/1874467214666210906125318.

ODor-evoked Autobiographical Memory in Alzheimer's disease?

El Haj M.

Arch Clin Neuropsychol. 2022 Feb 23;37(2):513-520. doi: 10.1093/arclin/acab074.

Nanotherapeutics for Alzheimer's Disease with Preclinical Evaluation and Clinical Trials: Challenges, Promises and Limitations

Bukhari SNA.

Curr Drug Deliv. 2022;19(1):17-31. doi: 10.2174/1567201818666210910162750.

Neuroinflammatory Signaling in the Pathogenesis of Alzheimer's Disease

Uddin MS, Kabir MT, Jalouli M, Rahman MA, Jeandet P, Behl T, Alexiou A, Albadrani GM, Abdel-Daim MM, Perveen A, Ashraf GM.

Curr Neuropharmacol. 2022;20(1):126-146. doi: 10.2174/1570159X19666210826130210.

Research Progress in Predicting DNA Methylation Modifications and the Relation with Human Diseases

Ao C, Gao L, Yu L.

Curr Med Chem. 2022;29(5):822-836. doi: 10.2174/0929867328666210917115733.

Phytotherapeutics against Alzheimer's Disease: Mechanism, Molecular Targets and Challenges for Drug Development

Gayathri S, Raghu CH, Fayaz SM.

CNS Neurol Disord Drug Targets. 2022;21(5):409-426. doi: 10.2174/1871527320666210920120612.

Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease

Sivaraman B, Raji V, Velmurugan BA, Natarajan R.

CNS Neurol Disord Drug Targets. 2022;21(5):427-449. doi: 10.2174/1871527320666210928160159.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias